Insuman infusat

Manufactured by Sanofi

Sourced in France

Insuman Infusat is a medical device used for the administration of insulin. It is a sterile, pre-filled disposable insulin cartridge that is compatible with certain insulin pump systems. The product is designed to deliver a continuous and controlled infusion of insulin to patients with diabetes.

Automatically generated - may contain errors

Lab products found in correlation

Phenol, by Novo Nordisk (1 mentions) Sb202190, by Bio-Techne (1 mentions) Su3327, by Bio-Techne (1 mentions) Apidra, by Sanofi (1 mentions) Recombinant human insulin, by Roche (1 mentions) M cresol, by Merck Group (1 mentions) Novorapid, by Novo Nordisk (1 mentions) Humalog, by Eli Lilly (1 mentions)

3 protocols using insuman infusat

Insulin Formulations and Kinase Inhibitors

Check if the same lab product or an alternative is used in the 5 most similar protocols

phenol (CAS No.108-95-2) and m-cresol (CAS No. 108-39-4) were obtained from Sigma–Aldrich. Jun N-terminal kinase (JNK) inhibitor SU3327 (10–20 μM in dimethyl sulfoxide (DMSO)) and p38 Inhibitor SB202190 (1–2 μM in DMSO) were from Tocris Bioscience.
The following formulations of insulin or insulin analogs were used, each at 100 I.U./ml: Apidra (3.15 mg/ml m-cresol, Sanofi-Aventis), Insuman Infusat (2.7 mg/ml phenol, Sanofi-Aventis), Humalog (3.15 mg/ml m-cresol, Eli Lilly), NovoRapid (1.72 mg/ml m-cresol and 1.5 mg/ml phenol, Novo Nordisk). Recombinant human insulin (Roche Diagnostics GmbH) was dissolved in phosphate buffer at 3 mg/ml (equivalent to 100 U/ml).

Weber C., Kammerer D., Streit B, & Licht A.H. (2014). Phenolic excipients of insulin formulations induce cell death, pro-inflammatory signaling and MCP-1 release. Toxicology Reports, 2, 194-202.

+ Open protocol

+ Expand

Implantable DiaPort Insulin Delivery

Check if the same lab product or an alternative is used in the 5 most similar protocols

The DiaPort system (Second Generation, Roche Diagnostics, Mannheim, Germany) which is surgically implanted is composed of a catheter located in the peritoneal space and fixed to a metallic body attached to the skin.^{20 (link)} A membrane and polyester felt aim to prevent skin infections. Patient skin grows on the felt and works as a barrier. The port, which sticks up 2 to 3 mm from the skin, can connect to the Accu-chek Spirit Combo pump (Roche Diagnostics, Mannheim, Germany) which delivers the insulin. Infused insulin through the DiaPort is a regular U-100 insulin solution (Insuman Infusat, Sanofi, Paris, France). Fast-acting insulin analogues are not usable in the DiaPort catheter because of their physical instability in this environment, which prompts insulin aggregation in the catheter lumen.^{20 (link)}

Dassau E., Renard E., Place J., Farret A., Pelletier M.J., Lee J., Huyett L.M., Chakrabarty A., Doyle FJ I.I.I, & Zisser H.C. (2017). Intraperitoneal insulin delivery provides superior glycaemic regulation to subcutaneous insulin delivery in model predictive control-based fully-automated artificial pancreas in patients with type 1 diabetes: a pilot study. Diabetes, obesity & metabolism, 19(12), 1698-1705.

+ Open protocol

+ Expand

High-fat diet induces obesity in mice

Check if the same lab product or an alternative is used in the 5 most similar protocols

Ten-week-old male mice (C57BL/6NRj) were caged in a group of 4 animals per cage and allowed to feed ad libitum on a high-fat diet (HFD) or normal diet (ND) (60% kcal from fat or 10% kcal from fat, respectively; D12492 [HFD] and D12450B [ND] Brogaarden, Denmark) for 12 weeks. Their body weight was recorded twice per week. Glucose- and insulin-tolerance tests were conducted in weeks 4 and 5, respectively, as well as in weeks 10 and 11. For glucose- and insulin-tolerance tests, the animals fasted for 5 h and were injected with 1 g/kg of BW glucose solution or 0.75 U/kg of BW insulin (Insuman Infusat, Sanofi) intraperitoneally. After 15, 30, 60, 90, and 120 min, blood glucose (tail vein) was measured with a blood glucose measuring device (Accu-Chek Aviva). After killing the animals using cervical dislocation, adrenal and pituitary glands and hypothalami were excised. The adrenal glands were cleaned from the surrounding fat tissue.
Starting at 6 weeks of age, male mice (C57BL/6 J) were fed a HFD or standard rodent chow for 20 weeks. The HFD (D05031101 M, Research Diets, New Brunswick, NJ, USA) containing 61.3% kcal from fat was used as a DIO model. Weekly weight gain and food intake were monitored. As a standard rodent chow, a V1534 diet (SSNIFF, Soest, Germany) containing 9.0% kcal from fat was used.

Werdermann M., Berger I., Scriba L.D., Santambrogio A., Schlinkert P., Brendel H., Morawietz H., Schedl A., Peitzsch M., King A.J., Andoniadou C.L., Bornstein S.R, & Steenblock C. (2020). Insulin and obesity transform hypothalamic-pituitary-adrenal axis stemness and function in a hyperactive state. Molecular Metabolism, 43, 101112.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!